AEON Biopharma Analyst Ratings
AEON Biopharma Analyst Ratings
While ratings are subjective and will change, the latest AEON Biopharma (AEON) rating was a initiated with a price target of $0.00 to $18.00. The current price AEON Biopharma (AEON) is trading at is $4.34, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | 314.75% | HC Wainwright & Co. | → $18 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/18/2023 | 314.75% | HC Wainwright & Co. | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for AEON Biopharma (AEON)?
永旺生物製藥（AEON）的目標價格是多少？
The latest price target for AEON Biopharma (AMEX: AEON) was reported by HC Wainwright & Co. on August 18, 2023. The analyst firm set a price target for $18.00 expecting AEON to rise to within 12 months (a possible 314.75% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月18日公佈了永旺生物製藥（美國證券交易所股票代碼：AEON）的最新目標股價。該分析公司將目標股價定爲18.00美元，預計永旺將在12個月內上漲至314.75％（可能上漲314.75％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for AEON Biopharma (AEON)?
AEON Biopharma（AEON）的最新分析師評級是多少？
The latest analyst rating for AEON Biopharma (AMEX: AEON) was provided by HC Wainwright & Co., and AEON Biopharma initiated their buy rating.
AEON Biopharma（美國證券交易所股票代碼：AEON）的最新分析師評級由HC Wainwright & Co. 提供，AEON Biopharma啓動了買入評級。
When is the next analyst rating going to be posted or updated for AEON Biopharma (AEON)?
永旺生物藥業（AEON）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AEON Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AEON Biopharma was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與永旺生物製藥的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。永旺生物製藥的最新評級是在2023年8月18日提交的，因此您應該預計下一個評級將在2024年8月18日左右公佈。
Is the Analyst Rating AEON Biopharma (AEON) correct?
分析師對永旺生物製藥（AEON）的評級是否正確？
While ratings are subjective and will change, the latest AEON Biopharma (AEON) rating was a initiated with a price target of $0.00 to $18.00. The current price AEON Biopharma (AEON) is trading at is $4.34, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的永旺生物製藥（AEON）評級最初的目標價爲0.00美元至18.00美元。永旺生物製藥（AEON）目前的交易價格爲4.34美元，在分析師的預測區間內。
